Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
批准号:
10855043
负责人:
Timothy An-thy Chan
金额:
$80.69万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-30 至 2024-11-30
关键词:
2019-nCoVACE2AccelerationAccidentsAcuteAdhesionsAffectAngiotensin IIAntibody ResponseAntigen ReceptorsB-Cell ActivationBlood TestsCOVID-19COVID-19 impactCOVID-19 mortalityCOVID-19 pneumoniaCOVID-19 riskCOVID-19 severityCOVID-19 survivorsCardiacCardiac MyocytesCardiopulmonaryCardiovascular DiseasesCardiovascular systemCathepsinsCause of DeathCellsCessation of lifeChronicClinicClinicalDataDiseaseDistantDown-RegulationEconomicsEndothelial CellsEndotheliumEnrollmentFailureFibrosisFoundationsFunctional disorderFutureGene ExpressionGene Expression ProfileGene Expression ProfilingGenetic TranscriptionGlucoseGoalsHealth PersonnelHeartHeart DiseasesHeart failureHeterogeneityHumanImmuneImmune System DiseasesImmunologicsImpairmentIn VitroIndividualInfectionInfection preventionInflammationInflammatoryIntegration Host FactorsInterleukin-6InterventionKnowledgeLeft Ventricular DysfunctionLifeLinkLipoproteinsLongitudinal cohortLymphopeniaMagnetic ResonanceMaintenanceMalignant NeoplasmsMeasuresModelingMolecularMolecular ProfilingMorbidity - disease rateNatureNodalOrganOutcomePathway interactionsPatientsPermeabilityPhenotypePilot ProjectsPlasmaPublishingRecoveryResearchRiskRisk FactorsSARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 pathogenesisScanningSerologySeveritiesShapesStimulusSurvivorsSymptomsT-LymphocyteT-Lymphocyte SubsetsTNF geneTechniquesTestingTissuesToxic effectVascular Endothelial CellVentricular DysfunctionViralViral PneumoniaVirusWorkadverse outcomecardiometabolismcardiovascular disorder riskcellular resiliencecohortcoronavirus diseasecytokinecytokine release syndromecytotoxicexperimental studygain of functionhigh riskimmune activationimmune functionimmune healthimmune system functionimprovedinternational centermonocytemortalitymultidisciplinaryneutralizing antibodypermissivenesspopulation healthpreventprospectiverecruitresponsesevere COVID-19single cell sequencingthrombotictranscription factortranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The objective of this proposal is to understand the immunologic foundations of heart disease which can occur
as a result of COVID19. Cardiac impairment, when it develops is often fatal, and our hypothesis is that the
maintenance of endothelial function is critical to surviving the protracted nature of COVID19 pneumonia,
especially in those with reduced or delayed antibody responses.
Our first aim will be to analyze those differences in immune function which pre-date infection but appear
to impact the risk of fatal COVID. This will be done by enrolling those at high risk for developing COVID19
(frontline healthcare workers), and performing serially assessments of their immunologic function if they develop
COVID. We will specifically investigate the mechanisms that link pre-infection inflammatory pathways to
protective serologic responses and symptom severity and recovery.
Our second aim will be to perform in vitro experiments to assess the requirements for endothelial cell
dysfunction and infectivity. We will compare various inflammatory and cardiovascular stimuli which seem to play
a role in promoting COVID19-related cardiovascular complications.
Our third aim is to characterize immune cells, endothelial cells, and cardiomyocytes in heart tissue from
those with COVID19-induced left ventricular dysfunction. Using single cell sequencing techniques, we will
determine cellular and molecular signatures that characterize the microenvironment of the COVID19-affected
heart, compared to appropriate controls.
Our conceptual model is that pre-existing immune dysfunction 1) reduces the efficiency of neutralizing
antibody responses, and 2) in conjunction with cardiovascular disease risk factors, induces endothelial
downregulation/depletion of nodal regulators which protect against inflammatory insults. This renders
endothelial cells unable to withstand COVID-specific stimuli. Once completed, this study will provide the
necessary information to improve the identification of those at risk for COVID-related heart disease and develop
rationale approaches to improve the improve survival in the setting of COVID.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.trsl.2021.11.005
发表时间:
2022-03
期刊:
Translational research : the journal of laboratory and clinical medicine
影响因子:
--
作者:
[Al-Kindi S, Zidar DA]
通讯作者:
Zidar DA
Crude lymphocyte levels: Can the past accelerate the future in preventive medicine?
粗淋巴细胞水平:过去能否加速预防医学的未来?
DOI:
10.1002/ajh.27125
发表时间:
2023
期刊:
American journal of hematology
影响因子:
12.8
作者:
[Zidar,DavidA]
通讯作者:
Zidar,DavidA
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10746700
-
项目类别:
-
资助金额:$3.7万
-
财政年份:2023
-
负责人:Timothy An-thy Chan
-
依托单位:
Project 3 Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint Blockade
-
批准号:10818969
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10916639
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10916640
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10875876
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10704661
-
项目类别:
-
资助金额:$147.36万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10526300
-
项目类别:
-
资助金额:$156.62万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10526301
-
项目类别:
-
资助金额:$9.33万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
-
批准号:10704713
-
项目类别:
-
资助金额:$16.46万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
-
批准号:10526303
-
项目类别:
-
资助金额:$19.32万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10704708
-
项目类别:
-
资助金额:$24.74万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10680625
-
项目类别:
-
资助金额:$67.37万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10222085
-
项目类别:
-
资助金额:$135.88万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10474453
-
项目类别:
-
资助金额:$99.2万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10706727
-
项目类别:
-
资助金额:$11.71万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCE
-
批准号:10201107
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Elucidating and targeting the molecular foundations of IDH Mutant glioma
-
批准号:10168250
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10252073
-
项目类别:
-
资助金额:$103.33万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10682519
-
项目类别:
-
资助金额:$99.2万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10264128
-
项目类别:
-
资助金额:$86.57万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位:
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
-
批准号:32302080
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:宋田源
-
依托单位:
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
-
批准号:82305216
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:姚骏凯
-
依托单位:
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
-
批准号:82305171
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:吴永灿
-
依托单位: